1 / 2

Anti-fungal Drugs Market to Exhibit 3.3% CAGR till 2027

Anti-fungal Drugs Market to Gain Significant Share from Merck & Co. Inc. and Astellas Pharma Inc. on Account of the Popularity of their Products

saurabhrj
Download Presentation

Anti-fungal Drugs Market to Exhibit 3.3% CAGR till 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Title : Anti-fungal Drugs Market to Exhibit 3.3% CAGR till2027 • Anti-fungal Drugs Market to Reach USD 13.17 Billion by 2027;Increasing Number of Infectious Skin Disorders to AidGrowth • Description : Anti-fungal Drugs Market to Gain Significant Share from Merck & Co. Inc. and Astellas Pharma Inc. on Account of the Popularity of theirProducts • Content: • The global anti-fungal drugs market sizeis likely to reach USD 13.17 billion by 2027 on account of the increasing prevalence of skin infections worldwide. Mycosis or fungal infection is a skin disease caused by a group of spore-producing organisms living and feeding on the human skin. When untreated, they lead to skin issues such as rashes, athlete’s foot, yeast infection, ringworm, nail fungus, bumps, and others. According to a recently published report by Fortune Business Insights™ titled, “Anti-Fungal Drugs Market Size, Share & Industry Analysis, By Drug Type (Echinocandins, Azoles, Polyenes, and Allylamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), By Route of Administration (Oral, Topical, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Others), and Regional Forecast, 2020-2027,” the market value was USD 10.24 billion in 2019, and will exhibit a CAGR of 3.3% between 2020 and 2027. • An Overview of the Impact of COVID-19 on thisMarket: • The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses acrossindustries. • However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by thepandemic. • We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for thefuture. • Click here to get the short-term and long-term impact of COVID-19 on this[Market]. • For More Information: • https://www.fortunebusinessinsights.com/industry-reports/antifungal-drugs-market- 101188 • ReportHighlights: • A 360-degree overview of themarket.

  2. Factors propelling, repelling, challenging, and offering lucrative growth opportunities to themarket. • Detailed analysis of the table ofsegmentation. • List of market manufacturers and the key strategies adopted bythem. • Significant Industry developments and other interesting insights into themarket. • Other anti-fungal drugs markettrends. • Market Drivers • Increasing Cases of Fungal Infections – Major GrowthDriver • Various factors are responsible for the anti-fungal drugs market growth. These include the increasing number of bacterial skin infections and other skin issues. Besides this, a rise in the number of cancer cases and the growth of hematopoietic stem cell transplantation have led to the increasing incidence of nosocomial infections that will further propel the market in the years tofollow. • On the contrary, arise in the availability of generic drugs among other expensive drugs for treating fungal infections may pose a major hindrance to the overall market. This, coupled with the strict rules imposed by the government on patent expiry and use of counterfeit drugs are expected to hamper the market. Additionally, the use of adverse drugs may result in hypokalemia, bone marrow suppression, nephrotoxicity, and others, thus posing major challenges to the market in the comingyears. • CompetitiveLandscape • Merck & Co. Inc. and Astellas Pharma Inc. Holding Dominant Positions inMarket • The global antifungal drugs market is dominated by companies such as Astellas Pharma Inc. and Merck & Co. Inc. because of their diverse portfolio. The success and popularity of products such as Mycamine and AmBisome by Astellas Pharma on the one side and Noxafilwilland Cancidas on the other will help these players attract high revenue in the coming years. Some of the vendors are also engaging inmergers and acquisitions, contracts and agreements, partnerships, and joint ventures to gain a competitive edge in the market during the forecastperiod. • More Trending Topics from Fortune BusinessInsights: • Europe Compression Bandages Market Share, Growth, Sales and Drivers Analysis Research Report 2026 • Europe Compression Bandages Market to Witness a Healthy CAGR of 5.2%; Advent of Efficient Pressure Bandages to Provide Impetus, says Fortune BusinessInsights

More Related